Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
boston blog main
boston top stories
clinical trials
fda
8
×
life sciences
national blog main
rna interference
8
×
alnylam pharmaceuticals
national top stories
new york blog main
new york top stories
deals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
boston
patisiran
regeneron pharmaceuticals
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
chris collins
cystic fibrosis
What
drug
fda
alnylam
bio
medicine
pharmaceuticals
rnai
roundup
ago
gene
medicines
patients
rna
time
acquire
afternoon
agreed
alliance
alnylam’s
alzheimer’s
approval
approve
approved
aren’t
awaits
billion
biological
brings
bristol
buy
calls
cash
caught
causing
changing
cholesterol
color
company
compound
congress
Language
unset
Current search:
photo
×
fda
×
" rna interference "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision